TRex Bio (TRXB) 10% Owner LLC Buys $2.5M of Stock
Alexandria Venture Investments has purchased 178,571 shares of TRex Bio, Inc., marking a substantial investment in the biotechnology firm.
Reviewed by automated data checks against the source filing. How we make and check alerts
Alexandria Venture Investments, LLC, 10% Owner at TRex Bio, Inc. ($TRXB), bought 178,571 shares at an average price of $14, worth about $2.50 million, on October 13, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $TRXB is up 3.0% to date (from the $13.60 close on Oct 13, 2026).
TRXB
TRex Bio, Inc.
Key Points
- Alexandria Venture Investments bought 178,571 shares of TRex Bio, Inc. for about $2.5 million on October 13, 2026.
- The recent trading price for TRex Bio is around $14.20, which is above its 50-day and 200-day moving averages by 2.5%.
- TRex Bio, Inc. has a market cap of approximately $384.5 million and focuses on developing biologics for autoimmune and inflammatory diseases.
Get $TRXB trade alerts by text
We text you when insiders, Congress or big funds trade $TRXB. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated TRex Bio, Inc. alert may contain errors. Disclosures
Alexandria Venture Investments, LLC bought 178,571 shares of TRex Bio, Inc. (TRXB) on October 13, 2026, for about $2,499,994 at a price of $14.00 per share. This purchase reflects a significant commitment, given that Alexandria is a 10% owner of the company.
TRex Bio, Inc. Stock Up 0.3%
As of October 16, 2026, TRex Bio recently traded around $14.20, which is above its 50-day and 200-day moving averages by 2.5%. However, it is about 8.4% below its 52-week high of $15.50, indicating potential for recovery.
Recent Earnings
TRex Bio, Inc. reported a trailing twelve-month EPS of -$2.47, reflecting its current stage in development and growth in the biotechnology sector.
About TRex Bio, Inc.
TRex Bio, Inc. focuses on developing immunoregulatory biologics aimed at treating autoimmune and inflammatory diseases. With its headquarters in South San Francisco, California, the company is actively working within the healthcare and biotechnology industries.
Bottom Line
Investors will be watching for further developments from TRex Bio, especially as Alexandria Venture Investments increases its stake. Keep an eye out for any future filings or earnings announcements that may provide more insights into the company's progress.
Related Filing Alerts
Source: Alexandria Venture Investments, LLC's Form 4 filing on $TRXB (Oct 13, 2026). Find the original filing: TRXB Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts